These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 11034065)

  • 1. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
    Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
    Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
    Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of the BRCA1 gene in sporadic breast cancer.
    Dobrovic A; Simpfendorfer D
    Cancer Res; 1997 Aug; 57(16):3347-50. PubMed ID: 9269993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
    Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
    Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
    Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
    Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
    Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
    J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.
    Ibanez de Caceres I; Battagli C; Esteller M; Herman JG; Dulaimi E; Edelson MI; Bergman C; Ehya H; Eisenberg BL; Cairns P
    Cancer Res; 2004 Sep; 64(18):6476-81. PubMed ID: 15374957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
    Kontorovich T; Cohen Y; Nir U; Friedman E
    Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
    Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
    Rathi A; Virmani AK; Schorge JO; Elias KJ; Maruyama R; Minna JD; Mok SC; Girard L; Fishman DA; Gazdar AF
    Clin Cancer Res; 2002 Nov; 8(11):3324-31. PubMed ID: 12429618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
    Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.